The Viral Activation Transfusion Study (VATS): Rationale, objectives, and design overview

Transfusion

Volumn 36, Issue 10, 1996, Pages 854-859

  Busch, M P ^a   Collier, A ^b   Gernsheimer, T ^c   Carrington, J D ^d   Flanigan, T P ^e   Kashkari, M ^f   Kennedy, M ^g   Kumar, P N ^c   Lane, T A ^a   Mellors, J W ^b   Mohandas, K ^d   Pollard, R B ^e   Viele, M ^f   Yomtovian, R ^g   Holland, P V ^b   Mccurdy, P R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; VIRUS REPLICATION;

EID: 10244235270     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.361097017169.x     Document Type: Article

References (65)

1. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41 (RR-17): 1 19.
2. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of human immunodeficiency virus type 1 (HIV-l) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994:139:1077-87.
3. Munoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune DeficSyndr 1992;5:694-700.
4. Saah AJ, Hoover DR, He Y, et al. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). Multicenter AIDS Cohort Study. J Acquir Immune DeficSyndr 1994;7:287-95.
5. Jacobson MA, PeiperI L, Volberding PA, et al. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion 1990;30:133-7.
6. Popovsky MA, Benson K, Classman AB, Hume H, Oberman HA, Pisciotto PT, Anderson KC. Transfusion practices in human immunodeficiency virus-infected patients. Transfusion 1995;35:612-6.
7. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
8. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
9. Henrard DR, Daar E, Farzadegan H, et al. Virologie and immunologie characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995:9:305-10.
10. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990;113:438-43.
11. Lee TH, Sheppard HW, Reis M, et al. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune DeficSyndr 1994;7:381-8.
12. Coombs RW, Henrard DR, Mehaffey WF, et al. Cell-free plasma human immunodeficiency virus type l titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J Clin Microbiol 1993;31:1980-6.
13. Piatak M Jr.Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993:259:1749-54.
14. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995:373:11722.
15. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995:332:209-16.
16. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995:373:123-6.
17. Cao Y, Qin L, Zhang L, et al. Virologie and immunologie characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
18. Lewis DE, Yoffe B, Bosworth CG, et al. Human immunodeficiency virus-induced pathology favored by cellular transmission and activation. FASEB J 1988;2:251-5.
19. Bednarik DP, Folks TM. Mechanisms of HIV-1 latency. AIDS 1992:6:3-16.
20. Sheppard HW, Ascher MS, McRae B, et al. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991;4:704-12.
21. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:I082-9.
22. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
23. Mole L, Ripich S, Margolis D, Holodniy M. Plasma HIV RNA levels are increased during active herpes simplex virus infection (abstract). Presented at the 2nd National Conference on Human Retroviruses, Washington, DC, 1995:98.
24. Schlechter GP, Soehnlen F, McFarland W. Lymphocyte response to blood transfusion in man. N Engl J Med 1972;287:1169-73.
25. Schechter GP, Whang-Peng J, McFarland W. Circulation of donor lymphocytes after blood transfusion in man. Blood 1977;49:651-6.
26. Dzik WH. Mononuclear cell microchimerism and the immunomodulatory effect of transfusion. Transfusion 1994;34:1007-12.
27. Lee TH, Donegan EA, Slichter SJ, Busch MP. Transient increase in circulating donor leukocytes following allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 1995;85:1207-14.
28. Cheung KS, Lang DJ. Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J Infect Dis 1977;135:841-5.
29. Olding LB, Jensen FC, Oldstone MBA. Pathogenesis ofcytomegalovirus infection. I. Activation of virus from bone marrowderived lymphocytes by in vitro allogenic reaction. J Exp Med 1975; 141:561-72.
30. Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993;81:1880-2.
31. Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent HIV-1 infection: implications for transfusion support of infected patients. Blood 1992;80:2128-35.
32. Klein HG. Wolf in wolf's clothing: is it time to raise the bounty on the passenger leukocyte? (editorial). Blood 1992;80:1865-8.
33. Ward JW, Bush TJ, Perkins HA, et al. The natural history of transfusion-associated infection with human immunodeficiency vims. N Engl J Med 1989;321:947-52.
34. Blumberg N, Heal JM. Evidence for plasma-mediated immunomodulation-transfusions of plasma-rich blood components are associated with a greater risk of acquired immunodeficiency syndrome than transfusions of red blood cells alone. Transplant Proc 1988;20:1138-42.
35. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-8.
36. Sloand EM, Kumar P, Klein HG, et al. Transfusion of blood products to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48-53.
37. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36:860-5.
38. Nusbacher J. Blood transfusion is mononuclear cell transplantation. Transfusion 1994;34:1002-6.
39. McCullough J, Yunis EJ, Benson SJ, Quie PG. Effect of bloodbank storage on leukocyte function. Lancet 1969;2:I333-7.
40. Mincheff MS, Meryman HT, Kapoor V, et al. Blood tranfusion and immunomodulation: a possible mechanism. Vox Sang 1993;65:18-24.
41. Busch MP, Lee TH. Role of donor leukocytes and leukodepletion in transfusion-associated viral infections. In: Sweeney J, Heaton WA, eds. Clinical benefits of leukodepleted blood products. Austin, TX: R.G. Landes Co., 1995:97-112.
42. Bowdcn RA. Transfusion-transmitted cytomegalovirus. Hematol/ Oncol Clin North Am 1995;9:155-66.
43. Thompson KS, Plapp FV, Long ND, Heenan TA. CMV infection in transplant recipients (abstract). Transfusion 1992;32(Suppl):65S.
44. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
45. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graftversus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a seconddegree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.
46. Ohto H, Anderson KC. Survey of transfusion-associated grafts vs-host disease in immunocompetent recipients. Transfus Med Revl996;10:31-43.
47. Adams PT, Davenport RD, Reardon DA, Roth MS. Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood 1992;80:551-5.
48. Ammann AJ. Hypothesis: absence of graft-versus-host disease in AIDS is a consequence of HIV-1 infection of CD4+T cells. J Acquir Immune Defic Syndr 1993;6:1224-7.
49. Habeshaw JA, Dalgleish AG, Hounsell EF. Absence of GVH diseases in AIDS (letter). J Acquir Immune Defic Syndr !994;7:1287-9.
50. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood I994;84:2061-7.
51. Mintz PD. Participation of HIV-infected patients in autologous blood programs (commentary). JAMA 1993;269:2892-4.
52. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-93.
53. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) séronégative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995:86:3599603.
54. Takahashi TA, Abe H, Hosoda M, et al. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter (letter). Transfusion 1995;35:967.
55. Lee TH, Stromberg RR, Heitman J, et al. Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA. Transfusion 1994;34:986-94.
56. Mulder J, McKinney N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
57. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of methods for the quantitation of plasma HIV-1 RNA. J Infect Dis 1994; 170:553-62.
58. Urdea MS. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin Chem 1993;39:725-6.
59. Spector SA, Wolf D, Salunga R. Human cytomegalovirus (HCMV) DNA detected in plasma by PCR predicts development of HCM V disease in patients with AIDS or following transplantation. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease: proceedings of the Fourth International Cytomegalovirus Workshop. Amsterdam: Excerpta Medica, 1993:225-30.
60. Miller MJ, Bovey S, Pado K, et al. Application of PCR to multiple specimen types for diagnosis of cytomegalovirus infection: comparison with cell culture and shell vial assay. J Clin Microbiol 1994;32:5-10.
61. Drew W, Miner R, Shen LP, Kolberg J. CMV antiviral agent susceptibility testing using branched DNA signal amplification (abstract). Presented at American Society for Microbiology Conference on Molecular Diagnostics and Therapeutics, Moran, WY, 1993.
62. Johnson D, Hirschkorn D, Busch MP. Evaluation of four alternative methodologies for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:522-30.
63. Aukrust P, Liabakk NB, Muller F, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologie, and virologie parameters. J Infect Dis 1994;169:420-4.
64. Liu Z, Hultin LE, Cumberland WO, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells in a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996;26:1-7.
65. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.